General Information of Drug (ID: DM9ZHRS)

Drug Name
LIM-0705
Indication
Disease Entry ICD 11 Status REF
Insulin-resistant disorder 5A44 Phase 2 [1]
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 382.21
Logarithm of the Partition Coefficient (xlogp) 0.2
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 6
Hydrogen Bond Acceptor Count (hbondacc) 10
Chemical Identifiers
Formula
C15H11O10P
IUPAC Name
[2-hydroxy-5-(3,5,7-trihydroxy-4-oxochromen-2-yl)phenyl] dihydrogen phosphate
Canonical SMILES
C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)OP(=O)(O)O)O
InChI
InChI=1S/C15H11O10P/c16-7-4-9(18)12-11(5-7)24-15(14(20)13(12)19)6-1-2-8(17)10(3-6)25-26(21,22)23/h1-5,16-18,20H,(H2,21,22,23)
InChIKey
UWJBYNLLMAPJMM-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
20833257
CAS Number
1111616-69-3
UNII
E2I4458LJN
DrugBank ID
DB12937
TTD ID
D06RIM
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ATP-binding cassette transporter (ABCA) TTK8XD6 NOUNIPROTAC Activator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01364155) Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR. U.S. National Institutes of Health.
2 WO patent application no. 2010,0428,86, Pyrone analogs for therapeutic treatment.